ABBV-400 in Select Advanced Solid Tumor Indications - Clinical Trial

What is the Purpose of this Study?


We are doing this study to find out if an experimental drug called ABBV-400 (the study drug) is a safe and effective option for treating various types of solid tumors.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Key Eligibility

Adults ages 18+ who are diagnosed with one of the following types of cancer that is advanced or metastatic:
- Hepatocellular carcinoma (HCC); OR
- Biliary tract cancer (BTC); OR
- Pancreatic ductal adenocarcinoma (PDAC); OR
- Esophageal squamous cell carcinoma (ESCC); OR
- Triple-negative breast cancer (TNBC); OR
- HR-positive and HER2-negative breast cancer (HR+/HER-); OR
- Head and neck squamous cell carcinoma (HNSCC)

For more information about who can join this study, please contact the study team at or 919-668-1861.

Age Group

What is Involved?


If you choose to join this study, you will:
- Get the study drug through an IV once every 3 weeks
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)

Study Details

Full Title
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00113960
NCT: NCT06084481
Phase I
Enrollment Status
Open for Enrollment